Evonik Begins GMP Lipid Production at New Indiana Manufacturing Center
Key Points
- Evonik completed its first GMP-grade lipid batch at its new Lipid Innovation Center in Lafayette, Indiana, with full capacity expected by mid-2027.
- The center's first product is PhytoChol, a non-animal cholesterol excipient for lipid nanoparticle formulations.
- LINC supports cancer immunotherapies, gene therapies and vaccines within Evonik's global development and manufacturing network.
Evonik has completed its first batch of Good Manufacturing Practice (GMP)-grade pharmaceutical lipids at its newly established Lipid Innovation Center (LINC) in Lafayette, Indiana, marking the start of production at the company’s expanded U.S. manufacturing operation. The facility is expected to reach full production capacity by mid-2027.
Located at Evonik’s Tippecanoe site, the new center is designed to support domestic production of specialized pharmaceutical lipids used in advanced drug delivery systems. The project received support from the U.S. government and is intended to strengthen the country’s supply chain for materials used in next-generation medicines.
LINC is equipped to manufacture multiple lipid classes and accommodate different production processes and product requirements. Its output will support applications ranging from cancer immunotherapies and gene therapies to vaccines targeting infectious diseases.
The facility’s first product is PhytoChol, a cholesterol excipient derived from non-animal sources that is used in lipid nanoparticle (LNP) formulations. Lipid components play an essential role in protecting and transporting nucleic acid-based therapeutics, including messenger RNA (mRNA). LNP technology gained significant visibility through its use in COVID-19 vaccines and is now being explored across a broader range of therapeutic applications. The global LNP market is projected to reach approximately $2.7 billion by 2034.
According to CHEManager Intl., the new facility represents an investment in the manufacturing infrastructure needed to support emerging RNA-based medicines. He also emphasized the importance of establishing reliable, large-scale U.S. production capabilities for pharmaceutical materials that ultimately support patient access to advanced treatments.
The Indiana operation is part of Evonik’s broader strategy to expand its position in lipid-based drug delivery while complementing its existing capabilities in oral and parenteral drug delivery and contract development and manufacturing (CDMO) services.
LINC will operate within Evonik’s international pharmaceutical development and manufacturing network, which brings together lipid chemistry, LNP formulation, process development, sterile manufacturing and regulatory expertise. The integrated structure is intended to support customers from early formulation research through clinical development and commercial production.
As programs advance into later-stage clinical development and commercial manufacturing, processes can be transferred to the company’s Birmingham, Alabama, operations. Lipids and adjuvants will be supplied through manufacturing locations in Dossenheim and Hanau, Germany, as well as the Tippecanoe site.
With the first GMP batch now produced in Indiana, Evonik is moving toward a more integrated supply model designed to connect specialized lipid production with formulation development and manufacturing of advanced pharmaceutical products.
Visit www.evonik.com to learn more.
Total Page Views: 12
